Providence Health & Services - Washington
Providence Health & Services - Washington was paid $43.26M by Medicaid between Jan 2018 and Dec 2024, across 320 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 20% of everything it billed.
SPOKANE, WA 99208
Next to other General Acute Care Hospital providers in Washington
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 210,940 | $7.16M | |
| 2019 | 219,591 | $8.04M | |
| 2020 | 197,848 | $6.77M | |
| 2021 | 206,461 | $7.20M | |
| 2022 | 183,953 | $5.99M | |
| 2023 | 155,264 | $4.41M | |
| 2024incomplete | 124,808 | $3.70M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 20% | 29,668 | 25,974 | $8.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 48,487 | 45,666 | $4.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.4% | 47,401 | 44,004 | $3.21M |
| S9480 | Intensive outpatient psychiatric services, per diem | 6.9% | 5,519 | 849 | $2.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 31,115 | 29,285 | $2.02M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.5% | 26,013 | 12,985 | $1.96M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 10,692 | 10,359 | $1.81M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.6% | 14,890 | 10,789 | $1.57M |
| J2323 | Injection, natalizumab, 1 mg | 3.2% | 1,114 | 1,010 | $1.37M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 4,446 | 4,326 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 8,001 | 7,681 | $1.05M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.2% | 2,514 | 2,437 | $961K |
308 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 8,695 | $928K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.0% | 1,519 | $851K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 9,831 | $719K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 8,533 | $656K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 3,800 | $620K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 2,690 | $614K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 3,503 | $581K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 3,139 | $452K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,439 | $320K |
| 80053 | Comprehensive metabolic panel | <1% | 65,094 | $305K |
| 95806 | <1% | 717 | $292K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,406 | $280K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,178 | $267K |
| 12001 | <1% | 1,128 | $229K | |
| 70496 | <1% | 1,522 | $228K | |
| 10061 | <1% | 1,106 | $226K | |
| 93971 | <1% | 2,628 | $219K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,331 | $213K |
| 95782 | <1% | 301 | $209K | |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 30 | $185K |
| 59025 | Fetal non-stress test | <1% | 1,182 | $184K |
| 96415 | <1% | 885 | $167K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 457 | $166K |
| 87631 | <1% | 3,711 | $163K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,870 | $142K |
| G0249 | Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests | <1% | 4,852 | $123K |
| 12011 | <1% | 383 | $95K | |
| 93017 | <1% | 970 | $89K | |
| 10060 | <1% | 429 | $86K | |
| 47562 | <1% | 37 | $81K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 260 | $74K |
| 12002 | <1% | 357 | $71K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,227 | $70K |
| 84484 | <1% | 15,002 | $69K | |
| 62323 | <1% | 376 | $67K | |
| 76801 | <1% | 922 | $63K | |
| 27447 | <1% | 12 | $57K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,651 | $52K |
| 87040 | <1% | 8,449 | $51K | |
| 43248 | <1% | 112 | $50K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,997 | $48K |
| 76937 | <1% | 656 | $48K | |
| 95800 | <1% | 474 | $47K | |
| 93975 | <1% | 1,114 | $45K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,021 | $44K |
| G0378 | Hospital observation service, per hour | <1% | 5,294 | $41K |
| 84145 | <1% | 4,760 | $37K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,308 | $36K |
| 70498 | <1% | 1,314 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 403 | $33K |
| 90715 | <1% | 1,921 | $33K | |
| 95811 | <1% | 80 | $32K | |
| 83605 | <1% | 6,390 | $32K | |
| 70486 | <1% | 1,307 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,112 | $29K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,070 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,879 | $26K |
| 83880 | <1% | 4,781 | $25K | |
| 96367 | <1% | 1,429 | $25K | |
| 85379 | <1% | 4,689 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,048 | $24K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,254 | $23K |
| 64483 | <1% | 42 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,475 | $21K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,707 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,979 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,408 | $18K |
| 80050 | General health panel | <1% | 3,254 | $17K |
| 76770 | <1% | 177 | $16K | |
| 97802 | <1% | 216 | $14K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 662 | $13K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,674 | $10K |
| 70544 | <1% | 127 | $10K | |
| 85027 | <1% | 11,633 | $10K | |
| 87641 | <1% | 1,072 | $10K | |
| 93970 | <1% | 110 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,117 | $10K |
| 86140 | <1% | 5,799 | $10K | |
| 94060 | <1% | 247 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,152 | $10K |
| 83735 | <1% | 8,990 | $9K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,972 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 299 | $9K |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 36 | $9K |
| 36430 | <1% | 142 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,349 | $7K |
| 88307 | <1% | 509 | $7K | |
| 29125 | <1% | 31 | $7K | |
| 97803 | <1% | 193 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,180 | $6K |
| 97161 | <1% | 206 | $6K | |
| 70491 | <1% | 68 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,985 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 473 | $5K |
| 64415 | <1% | 47 | $5K | |
| 80306 | <1% | 8,591 | $5K | |
| 86780 | <1% | 388 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,088 | $4K |
| 97597 | <1% | 91 | $4K | |
| 85652 | <1% | 1,607 | $4K | |
| 76870 | <1% | 52 | $4K | |
| 94729 | <1% | 217 | $4K | |
| 43235 | <1% | 13 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 525 | $4K |
| 82728 | <1% | 731 | $4K | |
| 80143 | <1% | 1,057 | $4K | |
| 85610 | <1% | 28,911 | $4K | |
| 81001 | <1% | 24,778 | $4K | |
| 82962 | <1% | 22,471 | $3K | |
| 87581 | <1% | 473 | $3K | |
| 87486 | <1% | 472 | $3K | |
| 84100 | <1% | 2,089 | $3K | |
| 84439 | <1% | 1,478 | $3K | |
| 80061 | Lipid panel | <1% | 908 | $3K |
| 85007 | <1% | 1,049 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 12 | $3K |
| 94726 | <1% | 162 | $3K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 12 | $3K |
| 45381 | <1% | 69 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34,708 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,326 | $2K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $2K |
| 83690 | <1% | 19,710 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,070 | $2K |
| 80179 | <1% | 1,015 | $2K | |
| 90686 | <1% | 239 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,572 | $2K |
| 73630 | <1% | 2,079 | $2K | |
| 73610 | <1% | 2,182 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 600 | $2K |
| 96376 | <1% | 10,362 | $2K | |
| 97162 | <1% | 97 | $2K | |
| 84702 | <1% | 2,294 | $2K | |
| 72100 | <1% | 1,539 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 20,381 | $2K |
| 74174 | <1% | 13 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,513 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 711 | $2K |
| 73030 | <1% | 2,049 | $2K | |
| 86850 | <1% | 2,112 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 991 | $2K |
| 74018 | <1% | 1,001 | $1K | |
| 83550 | <1% | 431 | $1K | |
| 83540 | <1% | 608 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,226 | $1K |
| 73130 | <1% | 1,882 | $1K | |
| 81025 | <1% | 19,333 | $1K | |
| 73502 | <1% | 1,212 | $1K | |
| 86901 | <1% | 2,204 | $1K | |
| 74019 | <1% | 614 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,301 | $1K |
| 81003 | <1% | 18,466 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,253 | $1K |
| 87070 | <1% | 1,830 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,316 | $944.89 |
| 82077 | <1% | 5,999 | $926.34 | |
| 87075 | <1% | 1,506 | $921.43 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $892.14 |
| 73560 | <1% | 776 | $891.23 | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,914 | $882.84 |
| 86900 | <1% | 2,140 | $868.85 | |
| 82550 | <1% | 1,570 | $855.23 | |
| 73562 | <1% | 1,122 | $847.03 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 29,877 | $824.72 |
| 87205 | <1% | 2,091 | $812.95 | |
| J3490 | Unclassified drugs | <1% | 1,327 | $796.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 14,850 | $783.54 |
| 82570 | <1% | 571 | $782.04 | |
| 86923 | <1% | 74 | $778.89 | |
| 73140 | <1% | 590 | $675.64 | |
| 80069 | <1% | 194 | $662.93 | |
| 73590 | <1% | 673 | $659.36 | |
| 82805 | <1% | 1,626 | $653.98 | |
| 73110 | <1% | 1,238 | $649.12 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,754 | $598.82 |
| 89051 | <1% | 84 | $594.23 | |
| 87077 | <1% | 2,238 | $565.31 | |
| 87186 | <1% | 3,316 | $555.34 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,544 | $522.47 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,282 | $505.29 |
| 85730 | <1% | 3,105 | $486.94 | |
| 84703 | <1% | 1,465 | $483.53 | |
| 87088 | <1% | 2,117 | $479.01 | |
| 81002 | <1% | 1,511 | $445.82 | |
| 84156 | <1% | 271 | $413.40 | |
| 73080 | <1% | 175 | $407.71 | |
| 71101 | <1% | 678 | $383.32 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,510 | $382.44 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,006 | $373.05 |
| 82607 | <1% | 80 | $367.36 | |
| 87420 | <1% | 21 | $365.80 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,065 | $351.10 |
| 87634 | <1% | 410 | $339.13 | |
| 73564 | <1% | 270 | $312.42 | |
| A9270 | Non-covered item or service | <1% | 11,784 | $303.01 |
| 87400 | <1% | 28 | $281.92 | |
| 73090 | <1% | 328 | $280.82 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,931 | $276.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,015 | $248.56 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,204 | $235.18 |
| 87210 | <1% | 936 | $229.79 | |
| 88342 | <1% | 1,295 | $207.03 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,761 | $170.48 |
| 84550 | <1% | 283 | $164.32 | |
| 82784 | <1% | 72 | $163.49 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,745 | $145.80 |
| C1769 | Guide wire | <1% | 1,384 | $141.59 |
| 90656 | <1% | 15 | $133.62 | |
| 84112 | <1% | 41 | $133.48 | |
| 87340 | <1% | 50 | $130.69 | |
| 87081 | <1% | 288 | $127.03 | |
| 85018 | <1% | 258 | $119.04 | |
| 87147 | <1% | 315 | $116.84 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,651 | $114.49 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,937 | $104.07 |
| 86803 | <1% | 29 | $102.87 | |
| 82105 | <1% | 25 | $102.67 | |
| 73660 | <1% | 28 | $94.20 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,756 | $90.87 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,084 | $81.12 |
| 80164 | <1% | 15 | $79.97 | |
| 85014 | <1% | 149 | $76.35 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,983 | $72.39 |
| 82945 | <1% | 27 | $71.54 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 285 | $70.22 |
| 82565 | <1% | 39 | $70.00 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,372 | $68.96 |
| 86364 | <1% | 12 | $65.08 | |
| 88304 | <1% | 948 | $64.20 | |
| 84157 | <1% | 31 | $52.75 | |
| 80076 | <1% | 15 | $50.69 | |
| 99152 | <1% | 56 | $50.43 | |
| 87493 | <1% | 39 | $46.74 | |
| 73070 | <1% | 30 | $40.53 | |
| 82746 | <1% | 14 | $36.57 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,495 | $32.29 |
| 82010 | <1% | 341 | $31.33 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,757 | $30.59 |
| 82803 | <1% | 60 | $29.31 | |
| 86592 | <1% | 29 | $27.86 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 177 | $27.20 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,913 | $22.32 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,846 | $22.17 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 36 | $17.84 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 119 | $17.51 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,328 | $11.87 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,110 | $11.40 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 716 | $10.62 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,449 | $10.34 |
| 36600 | <1% | 26 | $9.15 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 300 | $8.01 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,811 | $5.20 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 745 | $4.07 |
| 36591 | <1% | 29 | $3.93 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,289 | $1.98 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 312 | $1.74 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,172 | $0.08 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,813 | $0.04 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,288 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 15,935 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 379 | $0.00 |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 130 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 143 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 246 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 541 | $0.00 |
| 87806 | 0% | 148 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 95 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 716 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 174 | $0.00 |
| 96417 | 0% | 123 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 45 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 305 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 42 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 81 | $0.00 |
| J3415 | Injection, pyridoxine hcl, 100 mg | 0% | 67 | $0.00 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 0% | 60 | $0.00 |
| 29824 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 207 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 72050 | 0% | 12 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 903 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 734 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 179 | $0.00 |
| 74420 | 0% | 39 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 603 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 584 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 850 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 24 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 192 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 44 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 17 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 12 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 57 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 298 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 143 | $0.00 |
| 89060 | 0% | 14 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 108 | $0.00 |
| 96368 | 0% | 122 | $0.00 | |
| 73552 | 0% | 13 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 56 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 41 | $0.00 |
| 86308 | 0% | 14 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 27 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 68 | $0.00 |
| 88341 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.